Clinical Trials in Houston

Showing 13941-13960 of 17,108 trials

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

NCT00284804

This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.

Hodgkin's Disease

Bristol-Myers Squibb74 participantsStarted Nov 2005

Duarte, California, United States • Fresno, California, United States • La Jolla, California, United States +14 more locations

COMPLETEDPhase 2< 1 mile

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962

The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.

Hepatitis C Virus

Bristol-Myers Squibb512 participantsStarted Aug 2010

Montgomery, Alabama, United States • La Jolla, California, United States • Los Angeles, California, United States +69 more locations

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Find Trials by Condition in Houston

Phase II, 2nd Line Melanoma - RAND Monotherapy

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Elizabeth Registry for Low Grade Ovarian Cancer

PoC in Rheumatoid Arthritis With Methotrexate

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Ph IIA Study (SOC +/- NS5B)

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Pioglitazone in Early Parkinson's Disease

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes